Lipocine LPCN
NASDAQ LPCN
$2.08 -0.12 (-5.45%)
As of: Oct 1, 2026 · 12:12 PM EDT

Lipocine (LPCN) Change in Receivables (2013)

Updated

Lipocine's Change in Receivables was -$92,732 in Q3 2013.

Analysis

Lipocine (LPCN) Change in Receivables (2013) Analysis & Trends

For FY2012, Change in Receivables at Lipocine came in at -$313,753.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change Receivables (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn 1.35 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn 1.37 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn -
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn -
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn -
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn 1.09 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn 333.00 Mn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn -
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn 140.20 Mn
10 Lipocine 11.92 Mn -55.79 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2013 -92,732.00
Jun 30, 2013 -282,884.00
Mar 31, 2013 375,616.00
API Access

Lipocine Change in Receivables API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=change-in-receivables&ticker=LPCN&period=max&api_key=YOUR_API_KEY